PRTK
Income statement / Annual
Last year (2022), Paratek Pharmaceuticals, Inc.'s total revenue was $150.79 M,
an increase of 24.67% from the previous year.
In 2022, Paratek Pharmaceuticals, Inc.'s net income was -$63.57 M.
See Paratek Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$150.79 M |
$120.95 M |
$43.52 M |
$16.54 M |
$17.12 M |
$12.62 M |
$29,000.00 |
$0.00 |
$4.34 M |
$1.75 M |
Cost of Revenue |
$23.06 M
|
$21.54 M
|
$8.65 M
|
$3.48 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$127.73 M
|
$99.42 M
|
$34.87 M
|
$13.06 M
|
$17.12 M
|
$12.62 M
|
$29,000.00
|
$0.00
|
$4.34 M
|
$1.75 M
|
Gross Profit Ratio |
0.85
|
0.82
|
0.8
|
0.79
|
1
|
1
|
1
|
0
|
1
|
1
|
Research and Development Expenses |
$37.82 M
|
$30.35 M
|
$23.92 M
|
$39.55 M
|
$57.51 M
|
$60.07 M
|
$83.46 M
|
$50.77 M
|
$5.01 M
|
$6.90 M
|
General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$63.66 M
|
$36.97 M
|
$26.40 M
|
$19.99 M
|
$5.85 M
|
$12.43 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.82 M
|
Selling, General & Administrative Expenses |
$145.60 M
|
$119.40 M
|
$89.86 M
|
$89.14 M
|
$63.66 M
|
$36.97 M
|
$26.40 M
|
$19.99 M
|
$5.85 M
|
$19.25 M
|
Other Expenses |
-$9.48 M
|
-$9.21 M
|
-$3.41 M
|
-$31,000.00
|
-$44,000.00
|
-$34,000.00
|
$4,000.00
|
-$37,000.00
|
-$299,000.00
|
$2.96 M
|
Operating Expenses |
$173.94 M
|
$140.55 M
|
$110.37 M
|
$128.69 M
|
$121.17 M
|
$97.04 M
|
$109.86 M
|
$70.75 M
|
$10.86 M
|
$26.16 M
|
Cost And Expenses |
$197.00 M
|
$162.08 M
|
$119.02 M
|
$132.17 M
|
$121.17 M
|
$97.04 M
|
$109.86 M
|
$70.75 M
|
$10.86 M
|
$26.16 M
|
Interest Income |
$752,000.00
|
$66,000.00
|
$1.52 M
|
$3.57 M
|
$3.26 M
|
$1.38 M
|
$1.07 M
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$18.12 M
|
$17.41 M
|
$20.24 M
|
$16.40 M
|
$10.99 M
|
$5.08 M
|
$3.22 M
|
$770,000.00
|
$718,000.00
|
$0.00
|
Depreciation & Amortization |
$1.31 M
|
$445,000.00
|
$1.57 M
|
$3.54 M
|
-$1.07 M
|
$1.27 M
|
$2.30 M
|
$714,000.00
|
$196,000.00
|
$90,000.00
|
EBITDA |
-$44.90 M |
-$40.69 M |
-$73.93 M |
-$112.09 M |
-$100.83 M |
-$83.08 M |
-$106.46 M |
-$70.79 M |
-$6.62 M |
-$21.45 M |
EBITDA Ratio |
-0.3
|
-0.34
|
-1.7
|
-6.78
|
-5.89
|
-6.59
|
-3670.86
|
0
|
-1.53
|
-12.28
|
Operating Income Ratio |
-0.31
|
-0.34
|
-1.74
|
-6.99
|
-6.08
|
-6.7
|
-3775.38
|
0
|
-1.8
|
-15.67
|
Total Other Income/Expenses Net |
-$17.30 M
|
-$17.35 M
|
-$21.04 M
|
-$12.86 M
|
-$7.77 M
|
-$3.74 M
|
-$2.15 M
|
-$807,000.00
|
-$10.04 M
|
-$75,000.00
|
Income Before Tax |
-$63.51 M
|
-$58.48 M
|
-$96.54 M
|
-$128.49 M
|
-$111.85 M
|
-$88.32 M
|
-$111.64 M
|
-$70.86 M
|
-$17.84 M
|
-$27.45 M
|
Income Before Tax Ratio |
-0.42
|
-0.48
|
-2.22
|
-7.77
|
-6.53
|
-7
|
-3849.52
|
0
|
-4.11
|
-15.71
|
Income Tax Expense |
$57,000.00
|
$600,000.00
|
$19.72 M
|
$301,000.00
|
$502,000.00
|
$753,000.00
|
$3.23 M
|
$19,000.00
|
$419,000.00
|
$2.95 M
|
Net Income |
-$63.57 M
|
-$59.08 M
|
-$116.26 M
|
-$128.79 M
|
-$112.36 M
|
-$89.07 M
|
-$111.64 M
|
-$70.86 M
|
-$17.84 M
|
-$27.45 M
|
Net Income Ratio |
-0.42
|
-0.49
|
-2.67
|
-7.78
|
-6.56
|
-7.06
|
-3849.52
|
0
|
-4.11
|
-15.71
|
EPS |
-1.17 |
-1.22 |
-2.63 |
-3.93 |
-3.57 |
-3.32 |
-5.51 |
-4.29 |
-7.05 |
-17.54 |
EPS Diluted |
-1.17 |
-1.22 |
-2.63 |
-3.93 |
-3.57 |
-3.32 |
-5.51 |
-4.29 |
-7.05 |
-17.54 |
Weighted Average Shares Out |
$54.39 M
|
$48.42 M
|
$44.17 M
|
$32.79 M
|
$31.51 M
|
$26.83 M
|
$20.25 M
|
$16.50 M
|
$2.53 M
|
$1.56 M
|
Weighted Average Shares Out Diluted |
$54.39 M
|
$48.42 M
|
$44.17 M
|
$32.79 M
|
$31.51 M
|
$26.83 M
|
$20.25 M
|
$16.50 M
|
$2.53 M
|
$1.56 M
|
Link |
|
|
|
|
|
|
|
|
|
|